Fred Cavallo Aita

Fred Cavallo Aita

Auto-generated profile, based on publicly available information

Fred Cavallo Aita

Endocrinology Service, National Children’s Hospital, San José, Costa Rica

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2024 in Diabetologia
Verified
Journal Article
Open access
PDF file
RGRosaria Gesuita
Rosaria Gesuita
AEAlex Eckert
Alex Eckert
SBStéphane Besançon
Stéphane Besançon
NCNancy A. Crimmins
Nancy A. Crimmins
FCFred Cavallo
Fred Cavallo
OGon behalf of the SWEET study group
on behalf of the SWEET study group
Aims/hypothesis: The diagnosis of type 2 diabetes is increasing in young people worldwide. This study evaluated the frequency and clinical characteristics of young people presenting with type 2 diabetes from the multinational SWEET e.V Registry 2012–2021, including the first years of the COVID-19 pandemic. Methods: This is a longitudinal observational study based on the SWEET Registry, which collects demographic and clinical data on children and adolescents with diabetes from centres worldwide, with the diagnosis and classification of diabetes provided locally by each centre according to International Society for Paediatric and Adolescent Diabetes definitions. By July 2022, the SWEET Registry included 96,931 individuals from 130 centres with a total of 1,154,555 visits. Data were analysed by region: Europe (EU), Australia and New Zealand (AU/NZ), South America (SA), North America (NA) and Asia/Middle East and Africa (AS/AF). Trends in proportions for the two-year periods, calculated as cases with type 2 diabetes diagnoses over all cases with diabetes diagnoses, were estimated using logistic regression models adjusted for age at onset and sex. Results: Overall, there were 2819 of 58,170 new cases (4.8%) with type 2 diabetes: 614 in EU, 293 in AU/NZ, 79 in SA, 1211 in NA and 622 in AS/AF. The proportion of type 2 diabetes increased from 3.2% to 6.0% from 2012/2013 to 2020/2021, a relative rate of increase of 9% per two-year period (95% CI 5.9, 12.3; p<0.001). In the two-year period of the COVID-19 pandemic, type 2 diabetes continued to follow the observed trend, with a proportion of 6.0% in 2020–2021 compared with 5.4% in 2018–2019. High variability in the proportion of type 2 diabetes was observed across regions, with the lowest values observed in EU and the highest in NA. A significant increase in the proportion of type 2 diabetes was observed in EU, AU/NZ and NA. The median HbA1c was not uniform and was highest in AS/AF (85 mmol/mol [9.9%]; IQR 55–111 [7.2–12.3%]) and lowest in EU (63 mmol/mol [7.9%]; IQR 48–99 [6.5–11.2%]), and the difference between EU and NA (median value 73 mmol/mol [8.8%]; IQR 50–105 [6.7–11.8%]) was statistically significant (p=0.047). There was also a difference in BMI SD score by region: the lowest median BMI SD score was 2.2 (IQR 1.4–2.7) in AS/AF and the highest was 3.1 (IQR 2.5–3.6) in AU/NZ. Conclusions/interpretation: The multinational SWEET data from the years 2012 to 2021 inclusive support recent findings of a worldwide increase in type 2 diabetes in young people, albeit with regional differences. This increase highlights the need for ongoing preventive measures and available advanced treatment modalities worldwide. Graphical

15 April 2026 in Acta Medica Costarricense
Verified
Journal Article
Open access
FAFred Cavallo Aita
Fred Cavallo Aita
AGAlejandro Cob Guillén
Alejandro Cob Guillén
MGMichelle González-Rojas
Michelle González-Rojas
Cristina RodriguezCristina Rodriguez
Cristina Rodriguez
FSFrancis Ruiz Salazar
Francis Ruiz Salazar
LOLaura Ulate Oviedo
Laura Ulate Oviedo
Background: Continuous glucose monitoring has transformed diabetes care globally, yet no national guidelines exist in Costa Rica to guide its clinical use. This document aims to develop evidence-informed, context-specific recommendations for implementing continuous glucose monitoring in the Costa Rican healthcare system. Methods: We conducted a structured literature review focused on FreeStyle Libre 14-day and FreeStyle Libre 2 systems, including publications from 2015 through November 16, 2024. Ten clinical scenarios reflecting local practice needs were developed a priori. On February 1, 2025, six endocrinologists from Costa Rica’s public and private sectors convened in San José and employed a modified Delphi process with anonymous voting to approve recommendations at a prespecified threshold of≥80% agreement. Results: The panel issued 20 recommendations. Continuous glucose monitoring has been endorsed as the standard of care in type 1 diabetes and during pregnancy with type 1 diabetes. Selective use was supported in type 2 diabetes, especially for insulin-treated patients, those with hypoglycemia risk, and as a short-term educational tool, considering the particularities of the Costa Rican health care system. Use during hospitalization was recommended for stable patients able to self-manage. Routine use of continuous glucose monitoring in critically ill patients, individuals without caregiver support, or those receiving dialysis was discouraged. All uses should be paired with education and clinical oversight. Conclusions: These FreeStyle Libre 14-day and FreeStyle Libre 2 suggestions provide practical guidance for local implementation and identify priorities for future research, education, and health policy in Costa Rica.